Spero Therapeutics, Inc. (SPRO) Financial Statements (2026 and earlier)

Company Profile

Business Address 675 MASSACHUSETTS AVENUE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments52,88976,333109,107146,402126,90682,045
Cash and cash equivalent52,88976,333109,107112,58485,20929,730
Short-term investments    33,81841,69752,315
Other undisclosed current assets54,38754,8754,46311,47012,23913,369
Total current assets:107,276131,208113,570157,872139,14595,414
Noncurrent Assets
Operating lease, right-of-use asset3,1144,1555,1246,5307,1144,875
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization  23681,0261,6692,273
Other noncurrent assets1534355,7405,6445,2123,520
Other undisclosed noncurrent assets  46,590  31121
Total noncurrent assets:3,26751,18211,23213,20014,30610,689
TOTAL ASSETS:110,543182,390124,802171,072153,451106,103
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities15,2556,0487,3199,1366,3617,989
Employee-related liabilities5,8843,9182,630
Accounts payable7,3061,3786171,1011,1554,147
Accrued liabilities7,9494,6706,7022,1511,2881,212
Deferred revenue 3682,13210,3691,857  
Debt      928
Other undisclosed current liabilities33,45128,9733,9617,6777,98217,746
Total current liabilities:49,07437,15321,64918,67014,34326,663
Noncurrent Liabilities
Long-term debt and lease obligation 87966,1117,0684,866
Long-term debt, excluding current maturities 8796138177249
Liabilities, other than long-term debt14,77014,65027,1238,786  
Deferred revenue 12,21910,82522,1668,786  
Operating lease, liability2,5513,8254,9575,9736,8914,617
Other undisclosed noncurrent liabilities 57623,606 49,216(6,891) 
Total noncurrent liabilities:15,34638,34327,21964,1137,0684,866
Total liabilities:64,42075,49648,86882,78321,41131,529
Equity
Equity, attributable to parent46,123106,89475,93488,289132,04074,574
Preferred stock    33 
Common stock555352322919
Additional paid in capital505,706497,913489,760455,719409,722273,966
Accumulated other comprehensive income (loss)    (2)(7)16
Accumulated deficit(459,638)(391,072)(413,878)(367,463)(277,707)(199,427)
Total equity:46,123106,89475,93488,289132,04074,574
TOTAL LIABILITIES AND EQUITY:110,543182,390124,802171,072153,451106,103

Income Statement (P&L) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues47,977103,78153,50918,2569,33018,147
Gross profit:47,977103,78153,50918,2569,33018,147
Operating expenses(121,338)(82,300)(95,706)(106,227)(88,443)(81,363)
Operating income (loss):(73,361)21,481(42,197)(87,971)(79,113)(63,216)
Nonoperating income (expense)4,7953,923(4,218)(1,785)8332,291
Investment income, nonoperating4,7353,9371,1063464011,328
Other nonoperating income (expense)60(14)(55)(395)432740
Interest and debt expense   (3,581)   
Income (loss) from continuing operations before equity method investments, income taxes:(68,566)25,404(49,996)(89,756)(78,280)(60,925)
Other undisclosed income from continuing operations before income taxes   3,581   
Income (loss) from continuing operations before income taxes:(68,566)25,404(46,415)(89,756)(78,280)(60,925)
Income tax expense(2,600)(2,598)    
Income (loss) from continuing operations:(71,166)22,806(46,415)(89,756)(78,280)(60,925)
Loss before gain (loss) on sale of properties:(89,756)(78,280)(60,925)
Other undisclosed net income 2,600     
Net income (loss):(68,566)22,806(46,415)(89,756)(78,280)(60,925)
Other undisclosed net income (loss) attributable to parent    (44)(20)25
Net income (loss) attributable to parent:(68,566)22,806(46,415)(89,800)(78,300)(60,900)
Preferred stock dividends and other adjustments     (549) 
Other undisclosed net income available to common stockholders, basic   92,8304420 
Net income (loss) available to common stockholders, diluted:(68,566)22,80646,415(89,756)(78,829)(60,900)

Comprehensive Income ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net income (loss):(68,566)22,806(46,415)(89,756)(78,280)(60,925)
Comprehensive income (loss):(68,566)22,806(46,415)(89,756)(78,280)(60,925)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent   25(23)44
Comprehensive income (loss), net of tax, attributable to parent:(68,566)22,806(46,413)(89,751)(78,303)(60,881)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: